[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.87.3. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Letters
February 28, 2001

Underuse of β-Blockers Following Myocardial Infarction—Reply

Author Affiliations
 

Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorJody W.ZylkeMD, Contributing EditorIndividualAuthor

JAMA. 2001;285(8):1013. doi:10.1001/jama.285.8.1013

In Reply: Although we agree with Drs Budnitz and Neuman that implementation costs are conceptually relevant, including such costs would not have substantially changed our results or conclusions. Certainly there would have to be some intervention costs to increase β-blocker use but, as Budnitz and Neuman note, there are scant data on implementation costs. Furthermore, there are so many types of conceivable interventions—with a wide range of marginal costs and effects, as well as possible collateral benefits—that any such sensitivity analyses would be difficult to interpret.

First Page Preview View Large
First page PDF preview
First page PDF preview
×